Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
88%(7 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
5
56%
Ph phase_3
1
11%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 25 (55.6%)
Phase 31 (11.1%)

Trials by Status

terminated111%
completed889%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664
completedphase_3

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

NCT01728805
completedphase_2

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

NCT01226472
completedphase_1

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

NCT00888927
terminatedphase_1

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

NCT02444793
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01626664Phase 2

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Completed
NCT01728805Phase 3

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Completed
NCT01226472Phase 2

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Completed
NCT00888927Phase 1

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Completed
NCT02444793Phase 1

A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors

Terminated
NCT01173887Phase 2

Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15

Completed
NCT00920790Phase 2

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Completed
NCT01192984Phase 2

Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma

Completed
NCT00355472Phase 1

Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9